Medically reviewed by Dr. Alicia Moreno, PhD
Co-Occurring Disorders Editor & Mental Health · Last reviewed January 2025

Major depressive disorder (MDD) is one of the most prevalent and burdensome mental health conditions in the world. The NIMH estimates that 21.0 million U.S. adults — 8.3% of the adult population — experienced at least one major depressive episode in 2021. Depression is a leading cause of disability worldwide and is associated with significantly elevated mortality, primarily through suicide and the exacerbation of comorbid medical conditions.

What Is Major Depressive Disorder?

MDD is characterized by one or more major depressive episodes — periods of at least two weeks in which the person experiences a depressed mood or loss of interest or pleasure in almost all activities (anhedonia), along with at least four of the following: significant weight change, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue, feelings of worthlessness or guilt, difficulty concentrating, and recurrent thoughts of death or suicidal ideation.

The DSM-5 requires that these symptoms cause significant distress or functional impairment and are not attributable to substances, medical conditions, or another mental disorder. Critically, a depressed mood in the context of grief or loss does not automatically constitute MDD — but it can be, if the full criteria are met.

Persistent Depressive Disorder (Dysthymia)

Persistent depressive disorder involves a depressed mood for at least two years, with at least two additional depressive symptoms, that does not meet the severity threshold for MDD. It is often experienced as a chronic, low-grade depression that can be easy to dismiss as "just the way I am" — but it is a diagnosable condition that responds to treatment.

Depression and Addiction

Depression and substance use disorders are among the most common co-occurring conditions, with important bidirectional relationships. Alcohol use in particular is strongly associated with depressive symptoms — both because alcohol is a CNS depressant that worsens depression over time, and because individuals with depression frequently use alcohol to self-medicate. See our article on depression and addiction treatment for a full discussion of integrated treatment approaches.

Causes and Neurobiology

Depression is a heterogeneous condition with multiple contributing factors. The monoamine hypothesis — long the dominant model, attributing depression to serotonin or norepinephrine deficiency — has been substantially refined. Current models emphasize neuroplasticity, inflammation, HPA axis dysregulation, and glutamatergic signaling. Genetic factors account for approximately 37% of risk variance. Early adversity, chronic stress, medical illness, and certain medications are environmental contributors.

Evidence-Based Treatment

Psychotherapy

Cognitive Behavioral Therapy (CBT) has the most extensive evidence base of any psychotherapy for depression and is a first-line recommendation in virtually all clinical guidelines. CBT for depression targets negative automatic thoughts, maladaptive beliefs, and behavioral withdrawal patterns (behavioral activation). Interpersonal Therapy (IPT) is a comparably effective alternative, particularly for depression arising in the context of relationship transitions or grief.

Antidepressant Medications

SSRIs (selective serotonin reuptake inhibitors) — including sertraline, fluoxetine, escitalopram, and others — are the pharmacological first line for MDD. SNRIs (venlafaxine, duloxetine) are an effective alternative. Response rates in clinical trials average 50–60% for any individual antidepressant; when the first medication doesn't work, trying a second or third agent, or augmenting with another medication, increases the likelihood of remission.

Antidepressants are not "happy pills" — they do not produce euphoria in individuals without depression. They work gradually over 2–6 weeks to normalize the neurobiological dysregulation underlying depressive symptoms.

For Treatment-Resistant Depression

Electroconvulsive therapy (ECT) remains the most effective intervention for severe, treatment-resistant depression, with response rates of 60–80%. Transcranial magnetic stimulation (TMS) is an FDA-approved non-invasive option. Esketamine (Spravato), an intranasal ketamine-based medication, received FDA approval in 2019 for treatment-resistant MDD and for MDD with suicidal ideation.